<DOC>
	<DOCNO>NCT01486927</DOCNO>
	<brief_summary>This open-label , non-randomized , efficacy , safety pharmacokinetic ( PK ) study compare octocog alfa rVIII-SingleChain . The study consist three part , PK period ( Part 1 ) , continuation dose safety efficacy period ( Part 2 ) safety , efficacy , repeat PK period ( Part 3 ) also include surgical sub-study subject enrol Parts 2 3 .</brief_summary>
	<brief_title>An Open-label Safety , Efficacy Pharmacokinetic Study Recombinant FVIII Compared Recombinant Human Antihemophilic FVIII Patients With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Diagnosis severe hemophilia A defined &lt; 1 % FVIII : C document medical record . Males 18 65 year age ( Parts 1 2 ) . Males 12 65 year age ( Part 3 ) . Subjects receive currently receive FVIII product ( plasmaderived and/or recombinant FVIII ) &gt; 150 exposure day ( EDs ) FVIII product Written inform consent study participation obtain undergo study specific procedure . Any history current FVIII inhibitor Any first order family history FVIII inhibitor Use Investigational Medicinal Product within 30 day prior first rVIIISingleChain administration . Administration cryoprecipitate , whole blood plasma within 30 day prior administration rVIIISingleChain reference product . Known hypersensitivity ( allergic reaction anaphylaxis ) FVIII product hamster protein . Any known congenital acquire coagulation disorder congenital FVIII deficiency . Platelet count &lt; 100,000/ÂµL screening . Human immunodeficiency virus ( HIV ) positive subject CD4 count &lt; 200/mm3 , medical history screen available result older one year . ( HIV positive subject may participate study antiviral therapy permit , discretion Investigator ) . Subject currently receive IV immunomodulating agent immunoglobulin chronic systemic corticosteroid treatment . Subject serum aspartate aminotransferase ( AST ) serum alanine aminotransferase ( ALT ) value &gt; 5 time ( x ) upper limit normal ( ULN ) Screening . Subjects serum creatinine value &gt; 2 x ULN Screening . Evidence thrombosis , include deep vein thrombosis , stroke , pulmonary embolism , myocardial infarction arterial embolus within 3 month prior Day 1 . Experienced lifethreatening bleed episode major surgery orthopedic surgical procedure 3 month prior Day 1 .</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>